587 results on '"Hess,Lisa M"'
Search Results
102. Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices
103. Impact of gastric cancer treatment pathways on patient outcomes in a community oncology practice setting.
104. The Stories We Live: Finding God's Calling All Around Us, Kathleen A.Cahalan, Eerdmans, 2017 (ISBN 978‐0‐8028‐7419‐1), xiv + 138 pp., pb $15.99
105. Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: A meta-analysis
106. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
107. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
108. The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer.
109. Prevention of Gynecologic Malignancies
110. Challenges of Using ICD-9-CM and ICD-10-CM Codes for Soft-Tissue Sarcoma in Databases for Health Services Research
111. SUPPLEMENTAL_TABLES - Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
112. Chemotherapy-Related Change in Cognitive Function: A Conceptual Model
113. Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence
114. Fundamentals of cancer prevention
115. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study
116. Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice
117. Treatment and outcomes for patients (pts) with selected advanced/metastatic cancers by place of care.
118. HSR19-083: Treatment Heterogeneity and Overall Survival (OS) in Patients With Advanced/Metastatic Gastric/Gastroesophageal Junction Cancer (aGC/GEJ) in the United States
119. Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
120. Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
121. First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis
122. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study.
123. Application and comparison of generalized propensity score matching versus pairwise propensity score matching
124. Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy
125. Olaratumab for the treatment of patients (pts) with advanced/metastatic soft tissue sarcoma (STS): Treatment patterns in the United States (US) during the first year post-approval.
126. Real-world outcomes and patient (pt) characteristics for the second-line (2L) treatment of gastric, esophageal, or gastroesophageal junction (GEJ) adenocarcinoma (EGAC).
127. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States
128. Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups
129. Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).
130. Shadowdancing: Fear as a pathway to transformation
131. Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
132. Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol
133. Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040
134. Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer
135. Oncologist preferences in advanced soft tissue sarcoma: A discrete choice experiment.
136. Treatment sequences in non-small cell lung cancer in the United States from 2014-2016.
137. Geographic and site variability in the treatment of patients with metastatic gastric cancer.
138. PS01.72: Payer and Patient Out-of-Pocket Costs: A Projection of the Financial Burden of Non–Small Cell Lung Cancer Care in the United States Through 2040
139. MINI01.19: Cost Analysis of Pemetrexed-Platinum with Maintenance vs. Paclitaxel-Carboplatin-Bevacizumab with Maintenance in Patients with Lung Cancer
140. Factors Associated with Osteonecrosis of the Jaw among Bisphosphonate Users
141. The Patient Experience with Soft Tissue Sarcoma: A Systematic Review of the Literature
142. Abstract 2575: Adherence to oral oncolytics in patients with lung cancer
143. Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology Pharmacy
144. Understanding the patient experience with soft tissue sarcoma: A systematic review of the literature.
145. Physician decisions related to maintenance therapy for advanced non-small cell lung cancer (NSCLC) in the United States (US).
146. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study
147. Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S.
148. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
149. Patient Experience After Receiving a Diagnosis of Gastric Cancer in the USA.
150. Systematic Review of Brain Metastases in Patients With Non-Small-Cell Lung Cancer in the United States, European Union, and Japan.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.